Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 78
Inquire Before Buying

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 5, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Arno Therapeutics Inc
BioCryst Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Fab'entech SA
Integrated BioTherapeutics Inc
Johnson & Johnson
NanoViricides Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Sarepta Therapeutics Inc
Theravectys SA
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles
(Ebola + Marburg) (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1-E703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies for Ebola and Marburg Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVI-7288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eritoran tetrasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galidesivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GreEMTri - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-191N - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-78 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-69120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones
Featured News & Press Releases
Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates
Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract
Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection
Oct 31, 2014: Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates
Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
Jul 31, 2014: UTMB researchers receive over $6 million to develop treatment for deadly Ebola and Marburg viruses
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab'entech SA, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Sarepta Therapeutics Inc, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Theravectys SA, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2017
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • United States Metronidazole Market Report 2017
    Published: 21-Sep-2017        Price: US 3800 Onwards        Pages: 103
    In this report, the United States Metronidazole market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Me......
  • Global Cephalosporin Market Research Report 2011-2023
    Published: 19-Sep-2017        Price: US 3250 Onwards        Pages: 116
    Summary Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium" The global Cephalosporin market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content......
  • Global Cephalosporin Market Research Report 2017
    Published: 19-Sep-2017        Price: US 2900 Onwards        Pages: 155
    In the last several years, global market of Cephalosporin developed rapidly, with an average growth rate of 5.5%. In 2016, global revenue of Cephalosporin is nearly 3700 M USD; the actual production is about 18600 MT. This report studies Cephalosporin in Global market, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Union Chempharma NCPC Qilu Antibiotics Lupin Pharmaceutical......
  • Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017
    Published: 19-Sep-2017        Price: US 2000 Onwards        Pages: 54
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017, provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the mos......
  • Tetanus - Pipeline Review, H2 2017
    Published: 19-Sep-2017        Price: US 2000 Onwards        Pages: 71
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H2 2017, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgica......
  • Schistosomiasis - Pipeline Review, H2 2017
    Published: 19-Sep-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2017, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.Report Highlights......
  • West Nile Virus Infections - Pipeline Review, H2 2017
    Published: 19-Sep-2017        Price: US 2000 Onwards        Pages: 66
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2017, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form o......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2017
    Published: 19-Sep-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Drugs for Herpes Labialis (Oral Herpes) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Drugs for Herpes Labialis (Oral Herpes) in these regions, from 2012 to 2022 (forecast), covering - North Ame......
  • United States Drugs for Clostridium Difficile Infections Market Report 2017
    Published: 19-Sep-2017        Price: US 3800 Onwards        Pages: 115
    In this report, the United States Drugs for Clostridium Difficile Infections market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), marke......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs